NCT05793450已完成1 期
Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Pharmacokinetics (PK): Maximum Concentration (Cmax) of IBI362
研究概览
简要总结
The purpose of this study is to assess how fast IBI362 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •All Participants:
- •o The weight of male subjects is not less than 50 kg, and the body weight of female subjects is not less than 45 kg, and the body mass index (BMI) is within the range of 20~30 kilograms per meter squared (kg/m²), inclusive, at screening
- •Healthy Participants:
- •- Healthy males or females as determined by medical history, physical examination, and other screening procedures, with normal renal function, assessed by estimated glomerular filtration rate (eGFR) ≥90 milliliters per minute (mL/min) at screening
- •Participants with Renal Impairment:
- •Males or females with stable mild to severe renal impairment, assessed by eGFR
排除标准
- •All Participants:
- •Pregnant or lactating women, or men or women who are of childbearing potential and are not willing to use contraception within 6 months from the screening period to the administration of the study drug
- •Have known allergies to IBI362 or related compounds
- •Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2
- •Have serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5× the upper limit of normal (ULN) or total bilirubin (TBL) >1× ULN
- •Severe gastrointestinal diseases (such as active ulcer, pyloric obstruction, inflammatory bowel disease, etc.) occurred within 6 months before screening, or received gastrointestinal surgery or long-term use of drugs that directly affect gastrointestinal motility due to chronic gastrointestinal diseases
- •Have a history of acute and chronic pancreatitis, or serum amylase and/or lipase ≥ 1.5× ULN at screening, or fasting Triglyceride ≥ 5.64 mmol/L (500 mg/dl)
- •Participants with Renal Impairment:
- •obstructive urinary tract diseases (such as urinary stones, urinary tract obstruction caused by abdominal space-occupying lesions, etc.) or renal dysfunction caused by special types of renal parenchymal damage (such as polycystic kidney, medullary sponge kidney, Renal tumors, etc.) and/or patients with renal impairment who have diseases that are not related to renal disease but can cause renal impairment (eg, renal artery stenosis, acute drug injury, severe infection, hypovolemia, heart failure, etc.).
- •Have a history of kidney transplant
- •The treatment medication and/or the treatment medication of other comorbid diseases have been taken stably for less than 1 month at screening, or there are new medications within 1 month before screening (except temporary or intermittent use of drugs, such as Erythropoietin once a month, or diuretics as needed, etc.), or received any drug known to alter renal tubular creatinine secretion within 14 days or 5 half-lives before screening, such as cimetidine D, trimethoprim or cibenzoline, etc.
研究组 & 干预措施
IBI362 - Mild and Moderate Renal Impairment
Experimental
Group 2 - IBI362 administered SC to participants with mild and moderate renal impairment.
干预措施: IBI362 (Drug)
IBI362 - Healthy
Experimental
Group 1 - IBI362 administered subcutaneously (SC) to healthy participants with normal renal function.
干预措施: IBI362 (Drug)
IBI362 - Severe Renal Impairment
Experimental
Group 3 - IBI362 administered SC to participants with severe renal impairment.
干预措施: IBI362 (Drug)
结局指标
主要结局
Pharmacokinetics (PK): Maximum Concentration (Cmax) of IBI362
时间窗: Predose through 1344 hours postdose
PK: Area Under the Concentration Versus Time Curve (AUC) of IBI362
时间窗: Predose through 1344 hours postdose
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Clinical Study of IBI362 in Healthy Chinese Male SubjectsOverweight/ObesityNCT04773977Innovent Biologics (Suzhou) Co. Ltd.24
已完成
1 期
A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis PatientsHealthy ParticipantsAtopic Dermatitis PatientsNCT06193434Innovent Biologics (Suzhou) Co. Ltd.99
已完成
1 期
Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing ProcessesAcute Optic NeuritisMultiple SclerosisNCT02833142Biogen28
已完成
1 期
A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male VolunteersHealthy SubjectsNCT04868760Innovent Biologics (Suzhou) Co. Ltd.148
已完成
1 期
Drug-drug Interaction Trial Between Rifampicin and BI 409306 in Healthy VolunteersHealthyNCT03151499Boehringer Ingelheim15